Bon week-end a toutes/tous

Hello des idées d'achats..$ FTR  $ YTRA 👀

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) | Business Wire

ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) | Business Wire: ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimav

U.S. Dialysis Catheter Market Analysis & Outlook to 2024 - MedCore - ResearchAndMarkets.com | Business Wire

U.S. Dialysis Catheter Market Analysis & Outlook to 2024 - MedCore - ResearchAndMarkets.com | Business Wire: The

22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire

22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire: (美国商业资讯) -- 22nd Century Group, Inc. (NYSE American: XXII) 是一家植物生物技术公司，也是烟草减害和极低尼古丁烟草领域的领导者。公司今天宣布，已从北卡罗莱纳州立大学(NCSU)获得若干种尼古丁含量极低的烤烟和白肋烟植物品系的排他性授权。上述新植

PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q

PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q: PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors

recommandations

26/06/2018 | 08:56

    PARIS, 26 juin (Reuters) - Principaux changements de recommandations et/ou d'objectifs de
cours enregistrés mardi à Paris:
    
    * RENAULT           - Morgan Stanley a relevé sa recommandation à "pondération en ligne"
contre "sous-pondérer", avec un objectif de cours de 88 euros. 
    
    * DASSAULT SYSTEMES           - UBS, à "vendre" sur la valeur, a relevé son objectif de
cours à 112 euros contre 87,50 euros.
    
    * ARKEMA          - Barclays, à "surpondérer" sur la valeur, a abaissé son objectif de cours
à 121 euros contre 128 euros. 
    
    * ERYTECH PHARMA           - Jefferies, à l'achat sur la valeur, a abaissé son objectif de
cours à 36 euros contre 39 euros.

Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries

Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries

Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions | Business Wire

Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System

Dashboard - Meine Einschätzungen - sharewise.com

Dashboard - Meine Einschätzungen - sharewise.com

Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures

Medtronic Announces Second Bone Cement Solution Indicated for Treating Sacral Fractures

22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire

22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire: 22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA; Details available at www.clinicaltrials.gov

ＰＨＣホールディングス株式会社：薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire

ＰＨＣホールディングス株式会社：薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire: （ビジネスワイヤ） -- PHCホールディングス株式会社（本社：東京都港区）の100%子会社である、PHC株式会社（以下「PHC」）は、このたび、保険薬局用電子薬歴システム「PharnesV-MX」を発売しましたので、お知らせします。 PharnesV-MXは、薬剤師の業務改善を目指した新しい電子薬

Shire plc : Rule 2.9 Announcement

Shire plc : Rule 2.9 Announcement

ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire

ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire: ITM announced today that the U.S. FDA has accepted the Investigational New Drug Application to advance its radiopharmaceutical to a phase III trial

Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire

Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management Syste

ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain

ObsEva's EDELWEISS Trial Hits All Goals In Endometriosis-associated Pain

ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire

ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire: ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that t

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire: BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Transcatheter Valve

Bonne fête des papas

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire: Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCE